Terlipin powder for injection
Dexa Medica
Ingredients in every vial
| Terlipressin | 1 mg |
Each package contains
1 vial of 1 mg
Dosage form
 |
Powder for injection |
Dosage formPowder for Injection
Flavour
None
W.H.O. classification
H01C
H01C
A.T.C. Level 1
Anatomical Main group
H - Systemic hormonal preparations; excluding sex hormones and insulins
H01C
A.T.C. Level 2
Therapeutic subgroup
H01 - Pituitary and Hypothalamic Hormones and Analogues
H01C
A.T.C. Level 3
Pharmacological subgroup
H01C - Hypothalamic Hormones
Available in
 |
Indonesia |
Warnings
Alcohol
CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.
Machinery
CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.
Pregnancy
NOT RECOMMENDEDThis item is not safe for use during pregnancy.
Lactation
CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.
Indication
Bleeding esophageal varices
Terlipressin is indicated for the treatment of bleeding esophageal varices.
Terlipressin is indicated for the treatment of bleeding esophageal varices.
Dosage
18 TO 65 YEARS OLD
Initially, an intravenous (IV) injection of 2 mg terlipressin is given every 4 hours. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours. After the initial dose, the dose can be adjusted to 1 mg IV every 4 hours in patients with body weight <50 kg or if adverse effects occur.
0 TO 18 YEARS OLD
No data are available regarding dosage recommendation in these patient populations.
65 YEARS OLD AND ABOVE
No data are available regarding dosage recommendation in these patient populations.
Initially, an intravenous (IV) injection of 2 mg terlipressin is given every 4 hours. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours. After the initial dose, the dose can be adjusted to 1 mg IV every 4 hours in patients with body weight <50 kg or if adverse effects occur.
0 TO 18 YEARS OLD
No data are available regarding dosage recommendation in these patient populations.
65 YEARS OLD AND ABOVE
No data are available regarding dosage recommendation in these patient populations.